Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...
Mersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy Rating
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...
Mersana falls after early-stage trial data for lead cancer therapy
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
kalkinemedia22h
Mercedes-Benz car sales decline in 2024 amidst challenging market conditions
Mercedes-Benz experienced a decline in core car sales throughout 2024, reflecting a challenging year for the auto industry, ...
kalkinemedia22h
Mersana Therapeutics (NASDAQ: MRSN) Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment
Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment ...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...
Mersana Shares Rise on Advances With Breast-Cancer Treatment
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...